Rapid Litigation Management v. CellzDirect, Inc., No. 15-1570 (Fed. Cir. July 5, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellants seek review of the district court’s su m- mary judgment determination that U.S. Patent No. 7,604,929 (“’929 patent”) is invalid under 35 U.S.C. § 101. The district court concluded that the ’929 patent is directed to a patent-ineligible law of nature—that hepato- cytes are capable of survivin g multiple freeze -thaw c y- cles—and that the patente d process lacks the requisite inventive concept. Celsis In Vitro, Inc. v. CellzDirect, Inc. , 83 F. Supp. 3d 774 (N.D. Ill. 2015), supplemented, 94 F. Supp. 3d 940 (N.D. Ill.).